Study identifies SMARCA-deficient esophageal cancer as distinct subtype with MET amplification

Study involves analysis of resected tumors from patients with esophageal adenocarcinoma, a serious malignancy with significant morbidity and mortality.

Among the thousands who face esophageal adenocarcinoma each year, a new study of 722 resected tumors reveals that roughly one in nine harbors a molecularly distinct identity—defined by the loss of chromatin-remodeling proteins SMARCA2 and SMARCA4—that reshapes how the cancer grows, how the immune system responds, and ultimately how patients fare. Researchers at the University of Cologne have mapped this subtype's genetic amplifications, immune-stromal signatures, and a chromosomal loss that marks its most dangerous form, offering medicine a more precise language for a disease that has long res

Study identifies SMARCA-deficient esophageal cancer as distinct subtype with MET amplification

Cobertura Relacionada

Recibe The Register en tu bandeja